After Hours Gainer
CMPX Compass Therapeutics5.03-0.18-3.5%
After Hours:5.64+0.61 (+12.1%)
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
Globe NewswireFri, 24-Apr 4:00 PM
After Hours:5.66+0.63 (+12.6%)
CMPX Compass Therapeutics5.29+0.08 (+1.5%)
CMPX Compass Therapeutics5.31-0.11 (-1.9%)
CMPX Compass Therapeutics6.54+0.01 (+0.2%)
CMPX Compass Therapeutics6.09+0.24 (+4.1%)
